A biotechnology research facility classifies five experimental compounds—Candidate V, Candidate W, Candidate X, Candidate Y, and Candidate Z—for clinical trial priority according to a strict multi-attribute precedence rule.
Compounds are evaluated on three metrics:
- Toxicity Index (measured from to ; lower indicates safer compound)
- Receptor Affinity (measured from to ; higher indicates stronger binding)
- Bioavailability (measured as a percentage from to ; higher indicates better absorption)
Precedence Sorting Hierarchy:
1. Primary Criterion: Any compound with a Toxicity Index strictly less than takes absolute precedence over any compound with a Toxicity Index of or greater.
2. Secondary Criterion: Within the same toxicity category, compounds are sorted in descending order of Receptor Affinity.
3. Tertiary Criterion: If two compounds within the same toxicity category have identical Receptor Affinity scores, the compound with the higher Bioavailability is ranked higher.
| Compound | Toxicity Index | Receptor Affinity | Bioavailability |
|---|---|---|---|
| Candidate V | |||
| Candidate W | |||
| Candidate X | |||
| Candidate Y | |||
| Candidate Z |
Based on the classification and sorting criteria above, arrange the candidates in order from highest priority (Rank 1) to lowest priority (Rank 5).
- 1Candidate W
- 2Candidate Y
- 3Candidate V
- 4Candidate X
- 5Candidate Z